Clinical trials
Peptides clinical trials
Below are recruiting peptides clinical trials, each written for real people, not researchers. We’re tracking 144 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05870423RecruitingPhase 1
Testing PARP inhibitors with peptide radiation for NET
This early-phase study tests whether adding a medicine called a PARP inhibitor to peptide receptor radionuclide therapy (PRRT) can better control advanced or metastatic neuroendocrine tumors (NET). It may help by targeting tumor DNA repair while PRRT delivers targeted radiation.
Rotterdam, South HollandAges 18 years+ - NCT05879432RecruitingPhase 2
Peptide treatment to prevent or lessen kidney injury after heart surgery
This Phase 2 trial tests an LSALT peptide given around the time of “on-pump” heart surgery to help prevent or reduce acute kidney injury (a sudden drop in kidney function). It may help people who are at higher risk for kidney injury during or after surgery.
Calgary, AlbertaAges 18 years+ - NCT06132035RecruitingPhase 1
CG-P5 eye drops for wet macular degeneration
This study tests a new eye drop (CG-P5) for people with wet age-related macular degeneration. It aims to see if the drops are safe and may help improve vision.
Manchester, ConnecticutAges 50 years+ - NCT06463808Recruiting
Heart recovery after heart attack with added protein therapy
This trial tests if adding a protein called rhBNP (which helps the heart relax) to standard care after a heart attack and stent improves heart recovery and pumping strength over time.
Nanjing, JiangsuAges 18–75 - NCT06470295RecruitingEarly Phase 1
C-peptide's effect on low blood sugar response
This study tests whether C-peptide (a substance made by the pancreas) can help your body respond better to low blood sugar (hypoglycemia). It's a very early trial for people without certain health conditions.
Cincinnati, OhioAges 18–40 - NCT06510868Recruiting
MDS risk study for NET patients before or after PRRT
This study looks at the risk of developing Myelodysplastic Syndrome (MDS), a blood disorder, in people with Neuroendocrine Tumors (NET) who are treated with Peptide Radionuclide Therapy (PRRT). It involves a simple blood test to check for genetic changes linked to MDS. Participating can help understand and potentially prevent this side effect.
Toronto, OntarioAges Any age - NCT06564623RecruitingPhase 1
Peptide vaccine plus immunotherapy for biliary tract cancer
This trial tests a personalized peptide vaccine combined with two immunotherapy drugs (durvalumab and tremelimumab) for patients with biliary tract cancer whose tumors have specific genetic changes. The goal is to see if this combination can shrink tumors or slow their growth.
Baltimore, MarylandAges 18 years+ - NCT07688187RecruitingPhase 1
Theranostic pair for advanced kidney cancer
This trial tests a radioactive drug and its imaging partner to find and treat kidney cancer that has spread. You get a scan first to see if the cancer absorbs the drug, and if it does, you receive the therapy.
Omaha, NebraskaAges 18 years+ - NCT06751914Recruiting
Vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized vaccine made from your tumor's unique markers, combined with standard second-line treatment, for colorectal cancer that has grown after first treatment. It aims to see if this combination can help control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06751966Recruiting
Peptide vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized peptide vaccine (based on your tumor's unique markers) combined with standard third-line therapy for colorectal cancer that has progressed after two prior treatments. The goal is to see if adding the vaccine can help control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT07021859Recruiting
Migraine with aura study using CGRP to trigger attacks
This study tests whether a substance called CGRP (a protein linked to migraines) can safely trigger a migraine with aura in people who already have this condition. You'll receive an infusion and be monitored to see how your body responds.
Glostrup MunicipalityAges 18–65 - NCT06741072RecruitingPhase 1
Vaccine to prevent EBV-related cancer in transplant patients
This trial tests a vaccine (OSU-2131) that may help prevent cancers caused by the Epstein-Barr virus in people waiting for an organ transplant. The vaccine is designed to train your immune system to fight the virus.
Columbus, OhioAges 18–65 - NCT02600949Enrolling by invitationPhase 1
Peptide vaccine study for advanced pancreatic or colon cancer
This Phase 1 study tests a personalized vaccine made from a patient’s tumor to help the immune system recognize and attack cancer. It is for people with advanced pancreatic or colorectal cancer (often after surgery or while metastatic) and aims to see if the approach is safe and can help immune control of the cancer.
Houston, TexasAges 18 years+ - NCT07456449Recruiting
Collagen Peptides and Cellular Aging
This trial tests if taking collagen peptides can affect how your cells age. It may help people who are slightly overweight, not very active, and want to learn more about healthy aging.
Vienna, State of ViennaAges 50–70 - NCT07536100Recruiting
New Hair Growth Serum vs. Minoxidil for Hair Loss
This study compares a new peptide-based hair serum with minoxidil (a common hair-regrowth treatment) in people with androgenetic alopecia, a type of hair loss caused by genetics and hormones. The trial lasts 24 weeks and measures how well each treatment works.
Bangkok, BangkokAges 18 years+ - NCT07316361Enrolling by invitationEarly Phase 1
Personalized vaccine for high-risk endometrial cancer
This trial tests a personalized vaccine made from your tumor's unique proteins to help your immune system fight high-risk or advanced endometrial cancer. It is given along with your regular cancer treatments.
Thessaloniki, ThessalonikiAges Any age - NCT07140289Enrolling by invitation
GLP-1 drugs and stomach emptying before surgery
This study looks at how GLP-1 medications affect the time it takes for your stomach to empty before anesthesia. It may help doctors decide if you need to take special precautions before your surgery.
Detroit, MichiganAges 18–90 - NCT06581120Enrolling by invitation
Stomach ultrasound study for diabetes and obesity
This study uses ultrasound to see how GLP-1 RA medications (like Ozempic) affect the stomach in people with type 2 diabetes and obesity. It may help doctors better understand how these medicines work.
Cincinnati, OhioAges 10–25 - NCT05741242Enrolling by invitationPhase 1/Phase 2
Vaccine trial using customized immune targets for solid tumors
This trial tests a personalized cancer vaccine made from synthetic long peptide “neoantigens,” aiming to be safe and help the immune system fight certain solid tumors. It may fit people with pancreatic cancer after starting first-line chemotherapy, and some other solid tumors with limited options.
Beverly Hills, CaliforniaAges 12 years+ - NCT07773142Recruiting
Protein drink and exercise for muscle gain
This study looks at whether a special protein drink can help build muscle better than a placebo when combined with strength training. If you are a healthy young adult who is new to weight lifting, this trial may help you build muscle more effectively.
Birmingham, BirminghamAges 18–35 - NCT06218303RecruitingPhase 1
Vaccine for early breast cancer (DCIS)
This trial tests a vaccine that targets a protein (MUC1) found in early breast cancer cells. It's for women with ER+ DCIS who are planning surgery, to see if the vaccine can help prevent the cancer from coming back or getting worse.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06719856Recruiting
PET imaging study for multiple solid tumors
This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.
Beijing, Beijing MunicipalityAges 18–75 - NCT07111494RecruitingPhase 4
GLP-1 medication for psoriatic arthritis outcomes
This study tests if adding a GLP-1 medication (a type of drug that helps with weight and blood sugar) to your usual psoriatic arthritis treatment can improve your joint and skin symptoms. It is for people with psoriatic arthritis who have not yet achieved good control of their disease and have a higher body weight.
Milwaukee, WisconsinAges 18 years+ - NCT05232916RecruitingPhase 3
Vaccine for HER2-positive breast cancer after standard treatment
This trial tests a vaccine (GLSI-100) that may help prevent the return of HER2-positive breast cancer. It is given to patients who still had cancer cells after initial treatment with trastuzumab, or who had stage III disease and achieved a complete response.
Mobile, AlabamaAges 18–100
Hear when a new Peptides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for peptides?
- Yes. Clin2 currently lists 144 recruiting peptides studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a peptides trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a peptides trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.